The Daily Target 2X Short LLY ETF (LLYZ) is an equity ETF from Defiance designed to provide twice the inverse of the daily performance of Eli Lilly and Company. With a small AUM of $0.00B and an expense ratio of 1.29%, LLYZ offers a leveraged, short-term trading tool for investors seeking to capitalize on potential daily declines in Eli Lilly's stock price. The fund's concentrated strategy and leveraged nature make it a unique, high-risk, short-term investment vehicle. Past performance does not guarantee future results.
The Daily Target 2X Short LLY ETF (LLYZ) is an equity ETF from Defiance designed to provide twice the inverse of the daily performance of Eli Lilly and Company. With a small AUM of $0.00B and an expense ratio of 1.29%, LLYZ offers a leveraged, short-term trading tool for investors seeking to capitalize on potential daily declines in Eli Lilly's stock price. The fund's concentrated strategy and leveraged nature make it a unique, high-risk, short-term investment vehicle. Past performance does not guarantee future results.
ETF Overview
The Fund seeks daily inverse investment results, before fees and expenses, of two times (-200%) the daily percentage change in the share price of Eli Lilly and Company. The Fund does not seek to achieve its stated investment objective for a period other than a single trading day.
LLYZ aims to deliver twice the inverse of the daily percentage change in the share price of Eli Lilly and Company. This leveraged inverse strategy is designed for sophisticated investors seeking short-term tactical exposure to potential declines in Eli Lilly's stock. The fund rebalances daily, meaning it is not intended for long-term investment. Its top holding is First American Government Obligs X (FGXXX) at 21.44%, suggesting a portion of the fund's assets are held in short-term U.S. government securities to manage the leveraged exposure. With 100% of its exposure in 'Other' countries, the fund's geographic diversification is not a primary consideration. This ETF is best suited for experienced traders who understand the risks associated with leveraged and inverse products and who actively monitor their positions. Past performance does not guarantee future results.
Risk Metrics
LLYZ carries significant risks due to its leveraged and inverse nature. The 1.29% expense ratio is relatively high, which can erode returns, especially if the fund does not perform as expected. The fund's objective to deliver twice the inverse of Eli Lilly's daily performance means it is highly sensitive to short-term price fluctuations and is subject to daily compounding, which can lead to unexpected results over longer periods. The fund's concentration on a single company (Eli Lilly) amplifies company-specific risk. The fund's beta is 0.00, but this is less relevant given the fund's daily rebalancing and leveraged objective. Investors should be aware that LLYZ is designed for very short-term trading and is not suitable for buy-and-hold strategies. Past performance does not guarantee future results.
<a href="/etf/rklx">Daily Target 2X Long RKLB ETF (RKLX)</a> (Equity) — 1.31% expense ratio
<a href="/etf/pltz">Daily Target 2X Short PLTR ETF (PLTZ)</a> (Equity) — 1.29% expense ratio
<a href="/etf/sofx">Daily Target 2X Long SOFI ETF (SOFX)</a> (Equity) — 1.29% expense ratio
<a href="/etf/okll">Daily Target 2X Long OKLO ETF (OKLL)</a> (Equity) — 1.31% expense ratio
<a href="/etf/wdte">S&P 500 Weekly Distribution ETF (WDTE)</a> (Equity) — 1.03% expense ratio
<a href="/etf/ybmn">Defiance BMNR Option Income ETF (YBMN)</a> (Equity) — 0.85% expense ratio
Risk Metrics
Beta: 0.00
Questions & Answers
What is LLYZ and what does it track?
The Daily Target 2X Short LLY ETF (LLYZ) is an ETF offered by Defiance that aims to provide daily investment results, before fees and expenses, corresponding to two times the inverse (-200%) of the daily percentage change in the share price of Eli Lilly and Company. This means that if Eli Lilly's stock price decreases on a given day, LLYZ is designed to increase by twice that percentage, and vice versa. It is crucial to understand that LLYZ is designed for single-day investment objectives and should not be expected to provide the stated inverse leverage over longer time periods due to the effects of compounding. The fund's net asset value (NAV) is $8.55.
What is the expense ratio for LLYZ?
The expense ratio for LLYZ is 1.29%. This means that for every $10,000 invested in the fund, $129 is deducted annually to cover the fund's operating expenses. This expense ratio is significantly higher than the average expense ratio for equity ETFs, which is around 0.44%. The higher expense ratio reflects the complexities and costs associated with managing a leveraged and inverse ETF.
What are the top holdings in LLYZ?
As of 2026-03-15, the top holding in LLYZ is First American Government Obligs X (FGXXX), comprising 21.44% of the fund's assets. The fund holds 7 assets in total. While specific details on the other holdings are not available, the significant allocation to FGXXX suggests a strategy of using short-term U.S. government obligations to manage the fund's leveraged exposure and meet its daily investment objective. Investors should review the complete holdings list periodically for any changes.
Is LLYZ a good long-term investment?
LLYZ is generally not considered suitable for long-term investment. Its investment objective is to provide twice the inverse of the daily percentage change in the share price of Eli Lilly and Company. Due to the effects of compounding, the fund's performance over periods longer than a single day can deviate significantly from its stated daily objective. The fund's leveraged and inverse nature also introduces substantial risk, making it more appropriate for short-term tactical trading rather than long-term holding. Past performance does not guarantee future results.
How does LLYZ compare to similar ETFs?
LLYZ is unique in its focus on providing leveraged inverse exposure specifically to the daily performance of Eli Lilly and Company. While there are other leveraged and inverse ETFs available, most track broader market indices or sectors. LLYZ's expense ratio of 1.29% is higher than many non-leveraged ETFs. Given its specialized strategy and single-stock focus, LLYZ is not directly comparable to broad-based ETFs. Its AUM is $0.00B, indicating it is a relatively small and specialized fund.
Does LLYZ pay dividends?
According to the available data, LLYZ has a dividend yield of 0.00%. This indicates that the fund does not currently distribute any dividends to its shareholders. The fund's primary objective is to provide leveraged inverse exposure to the daily price movements of Eli Lilly, rather than generating income through dividends. Investors seeking dividend income should consider alternative investment options.